Impact of 2018 EU Risk Minimisation Measures and Revised Pregnancy Prevention Programme on Utilisation and Prescribing Trends of Medicinal Products Containing Valproate: An Interrupted Time Series Study

INTRODUCTION: Due to established teratogenicity of valproates, the EU risk minimisation measures (RMMs) with a pregnancy prevention programme (PPP) for valproate were updated in March 2018. OBJECTIVES: To investigate the effectiveness of the 2018 EU RMMs on valproate utilisation in five European cou...

Descripción completa

Detalles Bibliográficos
Autores principales: Abtahi, Shahab, Pajouheshnia, Romin, Durán, Carlos E., Riera-Arnau, Judit, Gamba, Magdalena, Alsina, Ema, Hoxhaj, Vjola, Andersen, Morten, Bartolini, Claudia, Kristiansen, Sarah Brøgger, Brown, Jeremy, Hallgreen, Christine Erikstrup, Garcia-Poza, Patricia, Gardarsdottir, Helga, Gini, Rosa, Girardi, Anna, Holthuis, Emily, Huerta, Consuelo, Ibánez, Luisa, Limoncella, Giorgio, Martín-Pérez, Mar, Paoletti, Olga, Roberto, Giuseppe, Souverein, Patrick, Swart, Karin M. A., Wing, Kevin, Sturkenboom, Miriam, Klungel, Olaf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252161/
https://www.ncbi.nlm.nih.gov/pubmed/37294532
http://dx.doi.org/10.1007/s40264-023-01314-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252161/
https://www.ncbi.nlm.nih.gov/pubmed/37294532
http://dx.doi.org/10.1007/s40264-023-01314-3

Ejemplares similares